A review published in Discover Oncology examines the functional roles of the long non-coding RNA MALAT1 in acute myeloid leukemia, a blood cancer that remains difficult to treat because relapse rates are high after initial therapy. The authors, led by Zahra Beyranvand and Roya Mahdavi, synthesize evidence that MALAT1 is consistently overexpressed in AML patients and is strongly associated with adverse clinical outcomes, including reduced overall survival, positioning it as both a candidate prognostic biomarker and a potential therapeutic target.
According to the review, MALAT1 acts as a multifaceted oncogenic driver in AML, promoting the proliferation, survival, migration and chemoresistance of leukemia cells through several distinct molecular mechanisms.
One of the best-characterized functions described is MALAT1’s activity as a competing endogenous RNA, often called a molecular sponge. In this role, MALAT1 binds and sequesters tumor-suppressive microRNAs, small regulatory RNAs that would otherwise restrain cancer-promoting genes. By soaking up these microRNAs, MALAT1 indirectly lifts the brakes on oncogenic signaling.
The review highlights a specific example: MALAT1 sequesters miR-146a, which leads to upregulation of C-X-C chemokine receptor type 4, or CXCR4, a receptor that supports enhanced leukemia cell survival. In a parallel mechanism, MALAT1 binds miR-96, and this interaction contributes to resistance against cytosine arabinoside, an antimetabolite chemotherapy drug that is a mainstay of AML treatment.
Beyond its sponge activity, MALAT1 exerts epigenetic control over the leukemia cell genome. The review describes how the lncRNA can recruit chromatin-modifying complexes such as Polycomb Repressive Complex 2 to silence tumor suppressor genes, including E-cadherin. This means MALAT1 does not merely regulate which messenger RNAs are available, but can physically reshape the packaging of DNA to switch protective genes off.
The authors also note that MALAT1 can regulate gene expression through interactions with RNA modification machinery, adding a further layer of regulatory control. Taken together, these mechanisms place MALAT1 at what the review calls the nexus of a complex regulatory network fundamental to AML pathogenesis and therapy failure.
The clinical implications cut in two directions. As a therapeutic target, its involvement in processes ranging from microRNA sponging to chromatin remodeling suggests that blocking MALAT1 might undermine several survival pathways at once, including the mechanisms that drive resistance to Ara-C chemotherapy.
The review’s conclusions are framed as a synthesis of emerging evidence rather than results from a new clinical trial, and the article was shared early as a peer-reviewed, accepted manuscript that is citable and carries a permanent DOI, with a final version of record to follow. Within that scope, the authors argue that targeting MALAT1 could offer a route to overcoming drug resistance and improving outcomes for AML patients, a disease where the search for novel molecular targets remains urgent.
Subject of Research: The role of the long non-coding RNA MALAT1 in acute myeloid leukemia progression and drug resistance
Article Title: Functional roles of lncRNA MALAT1 in acute myeloid leukemia
Article References: Beyranvand, Z., Mahdavi, R., Sadeghiattar, Z., Nazeri, Z., Salehi, A. M., Farzaneh, M., & Sheykhi-Sabzehpoush, M. (2026). Functional roles of lncRNA MALAT1 in acute myeloid leukemia. Discover Oncology. https://doi.org/10.1007/s12672-026-06193-5
Image Credits: AI Generated
DOI: 10.1007/s12672-026-06193-5
Keywords: acute myeloid leukemia, MALAT1, long non-coding RNA, microRNA sponging, chemoresistance, CXCR4, PRC2, epigenetics, prognostic biomarker, leukemogenesis, Functional, roles
News Source: Nathaniel Bowman. (October 29, 2026). MALAT1 Emerges as Central Driver of Leukemia Cell Survival and Drug Resistance. Scienmag.
